OmniSeq News

OmniSeq Names Dr. Shengle Zhang as New Lab Director

FOR IMMEDIATE RELEASE MEDIA CONTACT: Sawyer Lipari Lambert & Co. 313.309.9551 OmniSeq Names Dr. Shengle Zhang as New Lab Director Fast-growing cancer diagnostic laboratory continues focus on development of innovative product breakthroughs...

read more

Schoenborn named CEO at OmniSeq

June 26, 2019 Buffalo News - OmniSeq Inc., a molecular diagnostic laboratory on the Buffalo Niagara Medical Campus, has a new CEO. Margot P. Schoenborn, formerly the company's chief administrative officer, has been promoted to the position.

read more

People in the News

June 26, 2019 GenomeWeb - OmniSeq announced today that it has appointed Margot Schoenborn to succeed Mark Gardner as the firm's CEO.

read more

Margot Schoenborn becomes CEO of fast-growing OmniSeq

Business First - Margot Schoenborn has quite the resume. Now she gets to add yet another interesting professional experience: biotech boss. Schoenborn has been named the CEO of OmniSeq, which develops and sells molecular diagnostic tests that show cancer patients what...

read more

Follow Us on Twitter

November is #LungCancerAwarenessMonth. NCCN® recommends biomarker testing in #lungcancer be performed via a broad, panel-based approach, and to further consider RNA-based NGS to maximize detection of fusion events.@LabCorp @OmniSeq

A new laboratory and diagnostic industry coalition has been formed to advocate for insurance coverage for comprehensive genomic profiling. @labcorp @integratedoncology @illumina
#oncology #precisionmedicine

Get AMPed! Tomorrow from 1-2PM EST visit OmniSeq's Poster: ST20, Abstract: 917082, Category: Solid Tumors, Title: "Cancer-testis antigen detection by targeted RNA sequencing."

WATCH NOW! Learn how OmniSeq's Comprehensive Genomic Profiling (CGP) is becoming standard of care in oncology. @illumina
#Cancer #PrecisionMedicine #oncology #pathology #hope

Predictive Power of OmniSeq! #SITC2020 Thurs, Nov. 12(4:50-5:20 pm EST) and Sat, Nov. 14(1-1:30 pm EST) Poster#66:Complex markers of survival from pembrolizumab: the potential predictive role of tumor mutational burden (TMB) and KRAS.
#lungcancer #oncology

Load More...